Henry Ford Health Researchers Launch Clinical Trial Studying Therapy Aimed at Causing Brain Cancer Cells to Self-Destruct
The study focuses on high-grade astrocytomas and glioblastoma, which is the most malignant of all brain tumors.
DETROIT (June 8, 2023) – Researchers in the Hermelin Brain Tumor Center at Henry Ford Health are leading a Phase I clinical trial studying the maximum tolerated dose of an oncolytic adenovirus, a mutated virus engineered to selectively replicate in and destroy cancer tissue, in combination with fractionated stereotactic radiosurgery among patients who are undergoing resection of a recurrent high-grade astrocytoma brain tumor.
“The participants in this study have progressive high-grade astrocytoma as well as glioblastoma, and are scheduled to undergo repeat surgery,” said Tobias Walbert, M.D., Ph.D., principal investigator of the study and co-director of the Hermelin Brain Tumor Center at Henry Ford Health. “After the removal of as much tumor tissue as possible, a modified oncolytic adenovirus is injected into the wall of the resection cavity and any residual tumor tissue. The goal of this study is to determine the maximum tolerated dose of the injected adenovirus, which is engineered to selectively replicate in and destroy cancer tissue.”
This treatment is combined with a combination of oral 5-fluorocytosine and valganciclovir prodrug therapy, which are designed to only become toxic once they are inside tumor cells. This is known as “suicide-gene therapy,” as these prodrugs cause the tumor cells to self-destruct. Following the surgery to remove as much tumor tissue as possible, patients will be treated with fractionated radiosurgery, which is a process in which the total dose of stereotactic radiation is divided into several doses administered to the patient’s remaining brain tumor tissue on separate days of treatment.
“This study will help advance medical research data on oncolytic adenovirus mediated double suicide-gene therapy in patients with high-grade astrocytoma,” said Farzan Siddiqui, M.D., Ph.D., co-investigator of the study and radiation oncologist at Henry Ford Health. “Gathering data on the maximum tolerated dose in combination with fractioned stereotactic radiosurgery will be essential to understanding the full potential therapeutic benefit to patients.”
When a cancer cell self-destructs, the activated prodrug inside it may be passed on to neighboring tumor cells. This is known as a “bystander effect,” and it may allow a single infected cancer cell to not only destroy itself, but also several other cancer cells around it. Additionally, when cancer cells self-destruct in this manner, they may attract immune cells that work to clear the body of dead and dying cells. If many cancer cells self-destruct at once, it may potentially provoke an immune system response against any remaining tumor cells.
Since 1993, Henry Ford’s Hermelin Brain Tumor Center has been recognized by the National Cancer Institute (NCI) as a national leader for delivering leading brain tumor therapies. Henry Ford was among a select group of the nation’s centers, and the only one in Michigan, chosen to participate in the NCI-funded Adult Brain Tumor Consortium and Brain Tumor Trials Collaborative. As a major contributor to The Cancer Genome Atlas, a landmark cancer genomics program that molecularly characterized over 20,000 primary cancers, the Hermelin Brain Tumor Center at Henry Ford has the third largest tumor bank in the world with more than 3,000 brain tumor tissue samples and corresponding data for treatments and outcomes.
To learn more about the study, visit clinicaltrials.gov/ct2/show/NCT05686798.
MEDIA CONTACT: Jeff Adkins / firstname.lastname@example.org / 586-307-2027
About Henry Ford Health
Serving communities across Michigan and beyond, Henry Ford Health is committed to partnering with patients and members along their entire health journey. Henry Ford Health provides a full continuum of services – from primary and preventative care, to complex and specialty care, health insurance, a full suite of home health offerings, virtual care, pharmacy, eye care and other healthcare retail.
It is one of the nation’s leading academic medical centers, recognized for clinical excellence in cancer care, cardiology and cardiovascular surgery, neurology and neurosurgery, orthopedics and sports medicine, and multi-organ transplants. Consistently ranked among the top five NIH-funded institutions in Michigan, Henry Ford Health engages in more than 2,000 research projects annually. Equally committed to educating the next generation of health professionals, Henry Ford Health trains more than 4,000 medical students, residents and fellows every year across 50+ accredited programs.
With more than 33,000 valued team members, Henry Ford Health is also among Michigan’s largest and most diverse employers, including nearly 6,000 physicians and researchers from the Henry Ford Medical Group, Henry Ford Physician Network and Jackson Health Network.
The health system is led by President and CEO Robert G. Riney and serves a growing number of customers across 250+ locations throughout Michigan including five acute care hospitals, two destination facilities for complex cancer and orthopedics and sports medicine care, three behavioral health facilities, primary care and urgent care centers.